FDA wants label changes for certain ADHD drugs

06/29/2005 | MarketWatch

The agency, expressing concerns about hallucinations, suicidal thoughts and psychotic and violent behavior associated with methylphenidate products, says it plans to make labeling changes for that class of drugs used to treat attention deficit hyperactivity disorder. Those include Johnson & Johnson's Concerta and Ritalin from Novartis. The agency said it also is reviewing adverse event reports on Eli Lilly's Strattera and Shire's Adderall. Company representatives were not available for comment.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC